Cuprizone demyelination induces a unique inflammatory response in the subventricular zone by unknown
Hillis et al. Journal of Neuroinflammation  (2016) 13:190 
DOI 10.1186/s12974-016-0651-2RESEARCH Open AccessCuprizone demyelination induces a unique
inflammatory response in the
subventricular zone
James M. Hillis1, Julie Davies1, Mayara Vieira Mundim1,2, Osama Al-Dalahmah1 and Francis G. Szele1*Abstract
Background: Cuprizone leads to demyelination of the corpus callosum (CC) and activates progenitor cells in the
adjacent subventricular zone (SVZ), a stem cell niche which contributes to remyelination. The healthy SVZ contains
semi-activated microglia and constitutively expresses the pro-inflammatory molecule galectin-3 (Gal-3) suggesting
the niche uniquely regulates inflammation.
Methods: We studied the inflammatory response to cuprizone in the SVZ and CC in Gal-3 knockout mice using
immunohistochemistry and with the in vitro neurosphere assay.
Results: Cuprizone caused loss of myelin basic protein (MBP) immunofluorescence in the CC suggesting demyelination.
Cuprizone increased the density of CD45+/Iba1+ microglial cells and also increased Gal-3 expression in the CC.
Surprisingly, the number of Gal-3+ and CD45+ cells decreased in the SVZ after cuprizone, suggesting inflammation was
selectively reduced therein. Inflammation can regulate SVZ proliferation and indeed the number of phosphohistone H3+
(PHi3+) cells decreased in the SVZ but increased in the CC in both genotypes after cuprizone treatment. BrdU+ SVZ cell
numbers also decreased in the SVZ after cuprizone, and this effect was significantly greater at 3 weeks in Gal-3−/− mice
compared to WT, suggesting Gal-3 normally limits SVZ cell emigration following cuprizone treatment.
Conclusions: This study reveals a uniquely regulated inflammatory response in the SVZ and shows that Gal-3 participates
in remyelination in the cuprizone model. This contrasts with more severe models of demyelination which induce SVZ
inflammation and suggests the extent of demyelination affects the SVZ neurogenic response.
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Multiple sclerosis (MS) is a debilitating neurological
condition resulting from immune-mediated demyelin-
ation [1]. Various etiologies increase the risk of develop-
ing MS, including genetic and environmental origins,
but the exact causes are unclear [2]. Several different
murine models exist that partially recapitulate different
aspects of MS and demyelination [3]. Cuprizone is a
copper-chelator that impacts cell metabolism and leads
to demyelination, and if continued, eventual oligoden-
drocytic and neuronal death. Cuprizone is administered
via food for a defined time period before returning the* Correspondence: Francis.Szele@dpag.ox.ac.uk
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While the cuprizone model maintains an intact blood-
brain barrier with no T cell infiltration, it extensively ac-
tivates microglia and macrophages [4–6]. The cuprizone
model is increasingly used because of its reversibility
and reproducibility, reviewed in [7, 8].
Cuprizone treatment leads to demyelination in the cor-
pus callosum (CC). The CC in turn forms the roof of the
subventricular zone (SVZ), a neural stem cell niche that
generates neurons and glia throughout life [9]. The cupri-
zone model therefore enables investigation into the SVZ
response to demyelination and remyelination in the CC. A
recent fate-mapping study demonstrated that SVZ cells
contributed to remyelination in the CC after cuprizone-
induced demyelination [10]. These cells produced thicker
myelin than oligodendrocytes derived from localle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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ings are consistent with previous research showing SVZ
cells can differentiate into oligodendrocytes constitutively
as well as after demyelination [11–13] and indicate SVZ
cells migrate to the demyelinated CC in MS [13]. OPCs
may have broader reparative effects throughout the CNS
than SVZ cells, but SVZ-derived progenitors contribute to
repair around the lateral ventricles. This is clinically rele-
vant since it has been known for close to a century that
MS lesions frequently emanate from the ventricular
surface [14].
The SVZ thus provides a conveniently positioned nest
of stem cells that could benefit MS. Interestingly, data
from the past several years suggest inflammation is
uniquely regulated in the SVZ, often exhibiting features
dramatically different to the CC or other nearby regions.
We found that even in the absence of injury, CD45
levels and microglial proliferation were significantly
higher in the SVZ than in adjacent regions [15]. We re-
cently showed the SVZ expresses higher levels of che-
mokines than the nearby cerebral cortex [16]. These
chemokines rose markedly in the SVZ after Theiler’s
murine encephalomyelitis virus (TMEV) injections
which induce demyelination. However loss of Gal-3
blocked these increases, suggesting a pivotal role in the
inflammatory response in the TMEV model of demyelin-
ation [16]. Perhaps because of these differences, the SVZ
can exhibit inflammation in response to brain insults
unlike adjacent regions. Traumatic brain injury induced
massive inflammation in the CC, but all manifestations
of inflammation remained stable in the SVZ [15]. In
contrast, TMEV specifically targeted the SVZ and led to
greater inflammation there compared to surrounding re-
gions [16, 17]. We had reported in a preliminary study
that microglial density was maintained in the SVZ while
rising in the CC after cuprizone [17]. We therefore asked
if inflammation was differentially regulated in the SVZ
compared to the CC after cuprizone treatment. Initial
studies suggested that inflammation can be detrimental
to neurogenesis and brain repair [18, 19]. Further studies
have shown however that microglia can enhance neuro-
genesis in vitro and in vivo [20, 21]. Thus, it is important
to determine context-dependent inflammation in the
SVZ and how this affects the reparative potential of this
largest pool of endogenous brain stem cells.
Another clue that inflammation is uniquely regulated
in the SVZ is that the pro-inflammatory protein
galectin-3 (Gal-3) is homeostatically expressed in the
SVZ and RMS although elsewhere in the central nervous
system it is only detectable after injury [22]. Gal-3 has
been implicated in MS; it is expressed at high levels in
active lesions around the lateral ventricles, and it modu-
lates animal models of MS [16, 23]. Gal-3 was initially
termed Mac-2 because it was identified in activatedmacrophages [24]. However, in the SVZ, it is expressed
by astrocytes and ependymal cells and serves to maintain
speed and rostral directionality of SVZ neuroblast mi-
gration, thereby positively contributing to olfactory bulb
neurogenesis rates [22]. Gal-3 expression increases
leukocyte infiltration into the SVZ in the EAE and
TMEV demyelination models, leading to a worse pheno-
type [16, 25]. Gal-3 has also been reported to increase
oligodendrocyte differentiation in vitro and enhance
myelination in vivo [26] and loss of Gal-3 inhibited
oligodendrocyte maturation and microglial activation
after cuprizone [27]. Here, we hypothesized that
cuprizone-induced demyelination would cause SVZ in-
flammation and that Gal-3 would regulate SVZ progeni-
tor after cuprizone treatment.
Methods
Animals
129Sv wild-type mice (Gal-3+/+) were obtained through
the University of Oxford Biomedical Services Specific
Pathogens Free Breeding Unit. Gal-3 knockout mice on
a 129Sv background (Gal-3−/−) were obtained from
Françoise Poirier’s laboratory (Institut Jacques Monod,
Paris; Colnot et al., 1998). Gal-3+/+ and Gal-3−/− mice
were bred to produce heterozygote mice (Gal-3+/−),
which were subsequently mated with one another to
produce Gal-3+/+ and Gal-3−/− littermate controls. For
experiments using adult animals, these animals were
used. For experiments using postnatal animals, the litter-
mate controls were bred with other mice of the same geno-
type to produce entire litters of Gal-3+/+ or Gal-3−/− pups.
Animals were maintained in individually ventilated cages
on 12-h light/dark cycles with free access to food and water.
Procedures were performed with University of Oxford
Research Ethics Committee approval in accordance with
the Animals (Scientific Procedures) Act of 1986 (UK). All
efforts were made to minimize animal suffering and
distress.
Bromodeoxyuridine injections
To create label retaining SVZ cells, bromodeoxyuridine
(BrdU) was administered via intraperitoneal (IP) injec-
tion at 50 mg/kg. It was given in six 12-hourly doses
during the first 3 days of cuprizone administration.
Cuprizone administration
Cuprizone was administered at 0.2 % to 8-week-old male
and female mice ad libitum in chow (International
Product Supplies). Treated mice received cuprizone
chow for 3 or 6 weeks to cause demyelination, or 6 weeks
followed by 10 days of control chow to induce remyeli-
nation. Control mice received the same chow without
cuprizone. The 6-week cuprizone period was chosen as
oligodendrocytes decrease greatly by that time, while the
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~10 days of remyelination [28].
Fluorescent immunohistochemistry
Brains for immunohistochemistry were removed follow-
ing IP pentobarbitone overdose and transcardiac perfu-
sion with cold normal saline and 4 % paraformaldehyde
(PFA). They were postfixed in 4 % PFA overnight and
then cryoprotected in 30 % sucrose in 0.1 M phosphate
buffer. They were frozen in dry ice, stored at −80 °C and
then sectioned into 30-μm coronal sections using a
freezing microtome. Fluorescent immunohistochemistry
was performed as described previously [29]. Primary
antibodies are outlined in Table 1. BrdU antigen retrieval
was achieved with 1 M HCl at 38.5 °C for 1 h.
Microscopy
Epifluorescence images were obtained using a Leica
DMIRB microscope with a Hamamatsu C4742-95
digital camera or a Leica DMR microscope with a Leica
DFC-500 digital camera. Images were acquired in Open-
lab software (Improvision) and processed in Volocity 4
software (PerkinElmer), or acquired in Leica Firecam
3.4.1 software. Confocal images were obtained on a
Zeiss LSM 710 laser scanning confocal microscope
using the Z-stack and tile functions as appropriate. They
were analyzed in LSM Image Browser 4.2 (Zeiss). The
majority of imaging, including all images for threshold
analysis, used constant camera settings within a given
experiment.
Image analysis
All image acquisition, analysis and quantification, was
performed blinded to the genotype and treatment, ex-
cept for the initial acquisition of CC and cortical myelin
basic protein (MBP) images. The sections analyzed were
between Bregma 0.6 and 0.2 mm. The most caudalTable 1 Antibodies used in study
Antigen Dilution Host Manufacturer Product #
BrdU 1:500 Sheep Abcam ab1893
CD45 1:500 Rat Chemicon CBL1326
Dcx 1:100 Goat Santa Cruz sc-8066
Gal-3 1:100 Rabbit Santa Cruz sc-20157
Gal-3 1:100 Rat Santa Cruz sc-23938
GFAP 1:400 Rat Life Technologies 13-0300
Iba1 1:400 Goat Abcam Ab5076
Il1-β 1:100 Rabbit AbD Serotec AAM13G
Mash1 1:200 Mouse BD Pharmingen 556604
MBP 1:100 Goat Santa Cruz sc-13914
Olig2 1:1000 Rabbit Chemicon AB9610
PHi3 1:400 Rabbit Upstate 06-570sections where just anterior to crossing of the anterior
commissure. Live counting was used for BrdU+ and
phosphohistone H3 (PHi3+) cells in the SVZ and CC,
and Olig2+ cells in the SVZ. Sample images were ac-
quired of other cell markers and then counted using
ImageJ. Macros were developed that displayed only the
DAPI channel, so that the appropriate region could be
selected and cropped without the bias of seeing other
channels. The macros then switched the view to other
channels for cell counting. For MBP threshold analysis,
regions were initially selected using only the DAPI chan-
nel. Histograms for fluorescence intensity levels between
0 and 255 were then obtained. Microsoft Excel was used
to plot the intensity distribution and select an appropri-
ate threshold above which MBP labeling was considered
positive. The percentage of pixels with intensity greater
than the threshold value was then calculated.Real-time polymerase chain reaction
SVZ tissue from individual 6-week Gal-3+/+ and
Gal-3−/− mice was microdissected in Hanks’ Buffered
Saline Solution (HBSS). The sample was centrifuged
to pellet tissue and aspirate excess HBSS. It was
snap frozen in liquid nitrogen and stored at −80 °C.
RNA extraction was performed using an RNeasy
Mini Kit. Before extraction, individual samples were
pooled to provide three groups of four animals for
each genotype. All samples provided a 260/280 ratio
between 2.08 and 2.10, which was considered to pro-
vide satisfactory RNA quality. Reverse transcription
was performed using a High Capacity RNA to cDNA
Kit (Applied Biosystems). Quantitative PCR (qPCR)
used TaqMan Gene Expression Assays (Life Tech-
nologies) and TaqMan Gene Expression Master Mix
(Life Technologies). It was performed on a 7900HT
Fast Real-Time PCR System (Applied Biosystems)
using technical triplicates and standard curves and
following the TaqMan Gene Expression Master Mix
Protocol for 384-well plates. Data was initially ana-
lyzed using SDS Software v2.4, and aberrant repli-
cates were removed. EGFr and B2m had efficiency
between 90 and 110 % and R2 ≥ 0.998 while CCL2
had R2 = 0.965, Ccr2 R2 = 0.948, and Mmp9 R2 = 0.987 (Egfr
Mm00433023 m1; Ccl2 Mm00441242 m1; Ccr2
Mm00438270 m1; Mmp9 Mm00442991 m1; B2m
Mm00437762 m1). Galectin-1 (Lgals1) Mm00839408 g1;
Galectin-3 (Lgals3) Mm00802901 m1; Galectin-8 (Lgals8)
Mm01332239 m1; Galectin-9 (Lgals9) Mm00495295 m1.
Data were exported to Microsoft Excel, where individual
gene quantities were normalized to B2m and divided by
Gal-3+/+ quantities to create fold-change ratios. Statistics
were performed on normalized values using a Student’s t
test as described later.
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Primary SVZ cultures were obtained from P4-5 Gal-3+/+
and Gal-3−/− mice. Animals were sacrificed using
anesthesia (hypothermia) followed by decapitation.
Whole brains were dissected then cut into 500-μm cor-
onal sections using a McIlwain tissue chopper. SVZ was
microdissected in HBSS and stored on ice until dissec-
tion was complete. Cells were dissociated mechanically
with fine iris scissors and enzymatically through Accu-
tase incubation (Sigma, A6964) for 10 min at 37 °C.
Cells were then washed three times in Neurobasal A+
(1×, B27 1×, glutamine 2 mM and penicillin/strepto-
mycin 50k U/L) including centrifugation for 5 min at
1200 rpm for each wash, suspended in NB-A+ with
growth factors (EGF and FGF-2, 20 ng/ml, R&D Systems),
counted, and seeded in 96-well plates at 5 × 104/mL of NB-
GF. Cultures were incubated at 37 °C with 5 % CO2 for
7 days before whole wells were imaged using an AMF4300
EVOS® FL Imaging System (Life Technologies). Neuro-
spheres were aspirated and then dissociated enzymatically,
washed, suspended, counted, and seeded at 5 × 103/mL of
NB-GF. Cultures were then incubated for a further 7 days
before imaging of secondary neurospheres. Images were an-
alyzed in ImageJ using the Stack Sorter plugin to merge im-
ages (http://www.optinav.com/Stack-Sorter.htm).
Statistics
Data from the appropriate quantification was collated
into Microsoft Excel. It was then analyzed using scripts
written for SPSS 21. For experiments comparing one
factor between two groups, a Student’s t test was per-
formed. For experiments comparing one factor between
three or more groups, a one-way ANOVA was performed.
For experiments comparing two factors, a two-way
ANOVA was performed. For experiments comparing two
factors for a variable quantified in multiple SVZ or CC ana-
tomical regions, a repeated-measures ANOVA was per-
formed. Bonferroni post hoc tests were used to determine
significant pairwise comparisons in ANOVAs. Graphs were
produced in Prism 5 (GraphPad) and show mean ± stand-
ard error of the mean (SEM).
Results
We began by confirming demyelination in the CC, using
MBP immunohistochemistry to assess myelin levels. As
previously described, MBP is one of the key proteins associ-
ated with the myelin sheath [30, 31] and can be used to as-
sess demyelination and remyelination [27]. Gal-3 can affect
the inflammatory response in multiple models of disease
and injury [27, 32]. We did not detect differences in MBP
immunofluorescence between Gal-3+/+ and Gal-3−/− mice.
The CC, however, showed decreased MBP immunofluores-
cence in both genotypes after cuprizone (Fig. 1a, b), con-
firming CC demyelination as has been reported [33, 34].While the number or density of Olig2+ cells provides in-
formation on the number of oligodendrocyte-lineage cells,
it does not indicate how mature these cells are. We there-
fore performed co-immunohistochemistry with the mature
oligodendrocyte marker CC1 [35] (Fig. 1c). The labeling
demonstrated a good overlap between CC1 and Olig2 im-
munofluorescence (Fig. 1c). The CC1+ cells were inter-
preted as mature, myelinating oligodendrocytes. The
proportion of CC1+ oligodendrocytes increased with cupri-
zone treatment and then remyelination but was not af-
fected by Gal-3 loss (Fig. 1d). The effect between treatment
groups or interaction with genotype was not significant.
The number of Gal-3+ cells in the SVZ decreased after
cuprizone treatment
We previously showed that Gal-3 is selectively expressed
in the SVZ and regulates SVZ inflammation after injec-
tions of the demyelinating virus TMEV [16, 22]. We
therefore hypothesized that Gal-3 would have a role in
the SVZ response to cuprizone-induced demyelination.
Interestingly, the density of Gal-3+ cells decreased in the
SVZ following cuprizone treatment (N = 4 per group;
Fig. 2a, b). We included both dorsolateral SVZ astro-
cytes and ependymal cells in our quantification and
noted that Gal-3 was lost from both cell types. The
number of Gal-3+ cells/mm2 in control mice decreased
significantly after 3-week cuprizone (p = 0.009 compared
to control) and after 6-week cuprizone (p < 0.0005 com-
pared to control). The density then increased in the
remyelination treatment group (p = 0.034 compared to
6-week cuprizone). In contrast to the SVZ, Gal-3+ cell
density increased in the CC of control mice significantly
in the 6-week cuprizone group (p < 0.0005 compared to
control and p = 0.002 compared to 3-week cuprizone)
(Fig. 2c, d). The density then decreased in the remyelina-
tion group (p = 0.010 compared to control and p = 0.122
compared to 6-week cuprizone). These unexpected re-
sults showed that the regulation of Gal-3 expression
after cuprizone was opposite between the SVZ and the
CC, even though they are immediately adjacent.
We subsequently performed co-immunohistochemistry
to determine the identity of Gal-3+ cells (Fig. 2e–h).
They were mostly GFAP+ astrocytes or CD45+/Iba1+
microglia in both the SVZ and CC (N ≥ 4 for each
group; Fig. 2e). Mash1+ cells correspond to neural
lineage transit amplifying progenitor (TAP) cells in the
SVZ [36]. Similar to what we had shown before [22],
the occasional Mash-1+ TAP was also Gal-3+. There were
very few Gal-3+/Dcx + neuroblasts (1 Gal-3+/Dcx +
cell out of 337 Gal-3+ and 42 Dcx + cells counted in
the CC) or Olig2+ oligodendrocytes (2 Gal-3+/Olig2+
cells out of 337 Gal-3+ and 436 Olig2+ cells counted
in the CC). Interestingly, we found that the percentage
of CD45+/Iba1+ microglia in the CC expressing Gal-3
Fig. 1 MBP levels decrease in the CC after cuprizone treatment and effects of Gal-3 on CC1+ oligodendrocytes. a Representative images of MBP
immunohistochemistry in controls and after demyelination of Gal-3+/+ mice. Scale bar 100 μm. b Graph showing percentage of pixels above the
MBP threshold of 150. Statistics calculated as two-way ANOVA with N= 6. Graphs show mean ± SEM. **p< 0.01, ***p< 0.001. c Immunohistochemistry
showing co-localization of CC1 and Olig2. White arrows: CC1+/Olig2+. Yellow arrows: CC1-/Olig2+. Scale bar 50 μm. d Percent of Olig2+ cells that are CC1+.
Statistics were calculated as two-way ANOVA with N≥ 6. Graphs show mean ± SEM. **p≤ 0.01
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(p ≤ 0.001 for control compared to each other group)
(Fig. 2g). The percentage of astrocytes expressing Gal-
3 remained stable (Fig. 2f ). Overall, these data sug-
gested that Gal-3 expression increased mostly on
microglia in the CC after cuprizone.
The subventricular zone contained fewer hematopoietic
cells after cuprizone treatment
Previous work from our group showed that TMEV-induced
demyelination targets inflammation to the SVZ [16, 17].
Here, we further investigated the density of CD45+
hematopoietic cells and CD45+/Iba1+ microglia in the SVZ
and CC (Fig. 3a). The density of CD45+ hematopoietic cellsFig. 2 The number of Gal-3+ cells in the SVZ decreases after cuprizone tre
after cuprizone treatment. Scale bar 100 μm. White dotted lines define SVZ boun
and CC (d). Statistics calculated as one-way ANOVA with N= 4. Graphs show m
the SVZ from 6-week cuprizone or remyelination brains showing Gal-3 (green) c
CD45+ hematopoietic cells (which includes CD45+/Iba1+ microglia), and lack o
We used N= 4 for all groups. Dotted box shows magnified region. Scale bars 50
Statistics calculated as one-way ANOVA with N= 4 for f and g. No statistics perf
CD45+ cells were quantified in different experiments, so aggregates in h will nodecreased significantly in the SVZ yet increased in the CC
during cuprizone treatment (N ≥ 6 per group; Fig. 3b, c).
Although the density of CD45+ cells decreased in the SVZ
after cuprizone, the proportion that were Iba1+ microglia
was increased (Fig. 3d). This proportion, however, was simi-
lar across all conditions in the CC (Fig. 3e). There was no
difference between Gal-3+/+ and Gal-3−/− mice in the dens-
ity of CD45+ cells nor the percentage of CD45+ cells that
were Iba1+ in the SVZ and in the CC (Fig. 3b–e). Once
again, the juxtaposition of CD45+ density between the SVZ
and CC was noteworthy, as it suggested different inflamma-
tory processes occurring in the two neighboring regions.
We examined potential genes that might have compen-
sated for Gal-3 loss in the knockout mice and created aatment. a, c Representative images of Gal-3+ cells in the SVZ and CC
daries. b, d Graphs demonstrating the density of Gal-3+ cells in the SVZ (b)
ean ± SEM. *p< 0.05, **p< 0.01, ***p< 0.001. e Representative images of
olocalization with GFAP+ astrocytes/neural stem cells, Mash-1+ TAPs and
f Gal-3 colocalization with Dcx+ neuroblasts and Olig2+ oligodendrocytes.
μm. f–h Graphs showing the quantification of colocalization in the CC.
ormed for h. Graphs show mean ± SEM. ***p< 0.001. Note that GFAP+ and
t necessarily equal 100 %
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Gal-3−/− mice in previous qPCR and proteomic arrays and
genes thought to be regulated by Gal-3 which are relevant
for SVZ biology [16, 32]. qPCR on SVZ lysates obtained
from adult mice showed no difference between genotypes
for any of the genes (Additional file 1: Figure S1A). To in-
vestigate the possibility of Gal-3−/− receiving compensation
from other galectins, we carried out qPCR on SVZ samples
from Gal-3+/+ and Gal-3−/− littermates on galectins known
to be expressed in the SVZ (Allen Brain Atlas) and [37].
Lgals1, 8, and 9 also showed no difference between geno-
types (Additional file 1: Figure S1B). As expected, Lgals3
was absent in Gal-3−/− mice (p < 0.0005).
Oligodendrocyte-lineage cell density remained stable in
the SVZ but decreased in the corpus callosum after
cuprizone administration
Microglial cells and inflammation can influence oligo-
dendrogenesis in the SVZ [21]. We thereforeFig. 3 The number of CD45+ cells decreases in the SVZ after cuprizone treatm
the CC. Scale bar 100 μm. b, c Graphs demonstrating the density of CD45+ cell
cells that are Iba1+ in the SVZ and CC. Statistics calculated as two-way ANOVA
f Representative image of Olig2+ immunohistochemistry from the CC of a WT r
SVZ (g) and density in the CC (h). Statistics calculated using repeated-measures
Graphs show mean ± SEM. *p< 0.05, ***p< 0.001investigated the number of Olig2+ oligodendrocyte-
lineage cells in the SVZ following cuprizone treatment
(Fig. 3f–h) and found that the number of Olig2+ cells
remained constant, the SVZ taken as a whole across treat-
ment groups and genotypes (N ≥ 6 per group; Fig. 3g; p >
0.05 for relevant main effects and interactions in repeated-
measures ANOVA). Furthermore, when we separated the
SVZ into subregions (dorsolateral, striatal, ventral, septal,
and subcallosal), we found there were no differences that
occurred within subregions across treatment groups or ge-
notypes (p > 0.05 for relevant interactions in repeated-
measures ANOVA; data not shown). In contrast to the
SVZ, the density of Olig2+ cells in the CC decreased sig-
nificantly in the 3-week cuprizone treatment groups
(Fig. 3h). The density then returned to control levels
in the 6-week cuprizone and remyelination treatment
groups. This finding is consistent with the spontan-
eous remyelination that has previously been reported
around 5–6 weeks of cuprizone treatment [27].ent. a Representative images of CD45 and Iba1 immunohistochemistry in
s in the SVZ and CC. d, e Graphs demonstrating the proportion of CD45+
with N< 5. Graphs show mean ± SEM. *p< 0.05, **p< 0.01, ***p< 0.001.
emyelination mouse. g, h Graphs showing number of Olig2+ cells in the
ANOVA for SVZ and two-way ANOVA for CC with N= 6 for each group.
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cuprizone administration
It was important to determine if the reduced number of
CD45+ cells in the SVZ neurogenic niche was associated
with decreased astrocytosis. GFAP immunoreactivity in-
creased dramatically both in the SVZ and in the CC in
the 3-week, 6-week, and remyelination groups but with
no obvious qualitative differences between Gal-3+/+ and
Gal-3−/− mice (Fig. 4a, b).
Proliferation decreased in the SVZ but increased in the CC
after cuprizone
Most models of brain disease increase proliferation in
the SVZ [38]. Nevertheless, the reduced numbers of
Gal-3+ and CD45+ cells in the SVZ could have been as-
sociated with reduced proliferation since inflammation
can influence SVZ proliferation [20, 21]. We therefore
performed immunohistochemistry for PHi3+, which la-
bels proliferating cells in the mitoitc (M) phase of the
cell cycle [39]. In the SVZs, we found reduced numbers
of PHi3+ cells after 3 and 6 weeks of cuprizone treat-
ment, and they returned to baseline levels in the remye-
lination group (Fig. 5a, b, Additional file 2: Table S1). In
the CC, the number of PH3+ cells increased in the 6-
week cuprizone and remyelination groups (N ≥ 6 per
group; Fig. 5c). Thus, similar to the CD45+ and Gal-3+
cells, the number of Phi3+ cells decreased in the SVZ
but increased in the CC.
We previously showed that Gal-3 loss in KO mice did
not alter SVZ proliferation [16, 22, 32], and here, the
Gal-3+/+ and Gal-3−/− mice showed virtually the same
changes after cuprizone treatment (Fig. 5b, c). We found
no significant difference between Gal-3+/+ and Gal-3−/−
mice in the SVZ (p = 0.051 for the main effect in
ANOVA; p = 0.784 for the interaction of genotype withFig. 4 Reactive astrocytosis increases in the SVZ and CC with cuprizone tre
treatment. Dotted white line delineates CC from SVZ (note that SVZ was anthe treatment length in ANOVA) or the CC (p = 0.721
for the main effect; p = 0.421 for the interaction). To
confirm our findings on proliferation and to determine
if the decrease was due to loss of transit amplifying
progenitor cells, we carried out double immunohisto-
chemistry for the cell cycle marker Ki67 and for the
TAP marker Mash1 (Fig. 5d–g, Additional file 3: Figure
S2). Compared to controls, the number of Ki67+ cells
decreased significantly at the 3- and 6-week time
points (Fig. 5h), confirming the PHi3 results. We also
found statistically significant decreases in the number
of cells that were double positive for Mash1 and Ki67
(Fig. 5i). The number of Ki67+ cells and of Mash1
+/Ki67+ cells returned to control levels in the remyeli-
nation group. Similar to our data above, we did not ob-
serve effects of genotype on KI67+ or Mash1+/Ki67+
cell numbers in the SVZ. These experiments indicate
cuprizone treatment significantly reduces SVZ transit
amplifying cell proliferation and that they rebound
during remyelination.
Cuprizone feeding increases the expression of several
genes important for inflammation [40]. Il-1β is upstream
of many inflammatory processes, it increases prolifera-
tion in multiple cell types, and it drives SVZ neurogen-
esis [21]. We carried out Il-1β staining and found very
little labeling in the CC and SVZ of control mice (Fig. 5j)
and in the 3-week group. Il-1β expression in the CC and
SVZ increased in the 6-week cuprizone group (Fig. 5k)
and in the remyelination group. Whereas there was
moderate variablity in immunofluorescence within
groups of mice, we did not detect any obvious qualitative
differences between Wt and Gal-3−/− mice at any of the
time points (Fig. 5j, k).
To verify the lack of difference in proliferation be-
tween genotypes, we performed proliferation assays inatment. a, b Representative images of GFAP in the CC after cuprizone
alyzed in separate images of dorsolateral SVZ). Scale bar 50 μm
Fig. 5 SVZ proliferation decreases after cuprizone treatment. a High-magnification images of the dorsolateral SVZ comparing PHi3+ cells in
Gal-3+/+ and Gal-3−/− mice across treatment groups. Scale bar 100 μm. b, c Quantification of PHi3+ cells in the SVZ (b) and CC (c). d–g Example
of Ki67 and Mash1 double immunohistochemistry in the SVZ of a WT mouse in the remyelination group. Arrow points to a double-labeled cell.
Scale bar 50 μm. h, i Quantification of Ki67+ and Mash1+/Ki67+ cells in the SVZ. Statistics used were one-way ANOVA with Tukey’s post hoc test.
Graphs show mean ± SEM. *p < 0.05, **p < 0.01. j, k Il-1β immunohistochemistry in controls and the 6-week cuprizone group. Note that Il-1β was
barely detectable in controls but upregulated in the CC and SVZ in WT and Gal-3−/− mice in the 6-week cuprizone group. Scale bar 50 μm
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cells from P4 Gal-3+/+ and Gal-3−/− mice were cultured
for 7 days to produce neurospheres and then passaged
and cultured for a further 7 days for analysis (Fig. 6a).
Once again, there was no difference between genotypes.
The number of neurospheres was consistent for primary
neurospheres from Gal-3+/+ compared to Gal-3−/− mice
(p = 0.788) and secondary neurospheres (p = 0.346)
(Fig. 6c, d). The average diameter was consistent for pri-
mary and secondary neurospheres (p = 0.493; Fig. 6e, f ).
The distribution of neurosphere sizes was consistent be-
tween genotypes for primary and secondary neuro-
spheres (p > 0.05 for each comparison; Fig. 6g, h). This
in vitro data was consistent with all our in vivo data sug-
gesting SVZ proliferation is not altered in Gal-3−/− mice.
Gal-3 absence decreased the number of labeling retaining
SVZ cells after cuprizone treatment
We previously reported that loss of Gal-3 promotes SVZ
progenitor emigration into the corpus callosum after
TMEV injections [16], so we next asked if it also does so
after cuprizone. In order to label SVZ cells, we injected
BrdU at the beginning of the experiment (Fig. 7a). We
first looked for effects with all SVZ and CC subdivisions
combined (Fig. 7b). The number of BrdU+ cells left in
the SVZ 3 weeks after cuprizone chow was not altered
in WT mice (Fig. 7c, d). However, in Gal-3−/− mice,
there was a significant reduction in the number of
BrdU+ cells (Fig. 7d). At the 6-week and remyelination
time points, both WT and mutant mice had signifi-
cantly reduced SVZ BrdU+ cell numbers compared to
the 3-week group. These data suggest Gal-3 delays the
cuprizone-induced emigration of BrdU+ cells. TheFig. 6 Gal-3 loss does not alter neurosphere proliferation. a Diagram show
Scale bar 1 mm. c–h Graphs comparing Gal-3+/+ and Gal-3−/− mice for num
neurosphere sizes (g, h) for primary (c, e, and g) and secondary (d, f, and h
groups except Gal-3+/+ secondary neurospheres for which N = 3. Graphs shnumber of PHi3+ mitotic cells in the CC before cupri-
zone and at 3 weeks was minimal. However, we found
many BrdU+ cells in the CC at 3 weeks which is con-
sistent with them having migrated from the SVZ
(Fig. 7e, f ). Though more PHi3+ mitotic CC cells were
found in the 6-week and remyelination groups, the
number of BrdU+ cells decreased at this time point
(Fig. 7f ). We queried the identity of the emigrated
BrdU+ progenitor cells in the CC and found that only
a minimal number were positive for the neuroblast
marker doublecortin (data not shown). The SVZ gen-
erates oligodendrocyte progenitors in demyelinating
injuries [13], we therefore stained for Olig2. Across a
sample of brains (N = 3 per group), we found that
56 % (117 out of 208 cells) of BrdU+ cells were Olig2+
(Fig. 7g).
We next looked for effects in individual SVZ and
CC subdivisions (Fig. 7b). With further breakdown
using pairwise comparisons, the key difference was
fewer BrdU+ cells in the Gal-3−/− compared to Gal-3+/+
SVZ after 3-week cuprizone specifically in the dorsolateral
(p = 0.001) and ventral (p = 0.006) SVZ (Additional file 4:
Table S2). When comparing control and cuprizone mice,
there was an increase after cuprizone treatment in the med-
ial CC (p = 0.007; Additional file 5: Table S3). The number
of cells in the lateral CC did not change significantly from
control to cuprizone mice (p = 0.852).
Demyelination occured in the olfactory bulbs after
cuprizone treatment
We noticed MBP loss in several brain areas after
cuprizone feeding and examined this more carefully
in the olfactory bulb (OB), the target structure ofing experimental outline. b Sample image of primary neurospheres.
ber of neurospheres (c, d), average diameter (e, f), and distribution of
) neurospheres. Statistics performed using t tests with N = 5 for all
ow mean ± SEM
Fig. 7 BrdU+ label retaining cells after cuprizone treatment. a BrdU regimen administered to mice. b Subdivisions of the SVZ and CC that were
quantified. c, e Representative images showing BrdU immunohistochemistry in Gal-3+/+ and Gal-3−/− mice in the dorsolateral SVZ (c) and CC (e).
White dotted lines delineate region of interest. White arrows show examples of BrdU+ cells. d, f Graphs showing quantification of BrdU+ cells in
the SVZ overall (d) and CC overall (f). In addition to the statistics shown, cuprizone-treated mice had significantly fewer cells than control mice for
all genotype/treatment combinations (p≤ 0.011) except 3-week Gal-3+/+. g Example of BrdU+ cells that were Olig2+ (white arrows) and a BrdU+/Olig2- cell
(yellow arrow). Statistics calculated as repeated-measures ANOVA with N≥ 3. Graphs show mean ± SEM. ***p< 0.005. Scale bars 100 μm
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and then return of MBP expression in the glomerular,
external plexiform, mitral cell, and internal plexiform
layers (Additional file 6: Figure S3a and b; N = 6 per
group).Discussion
This study showed that the number of Phi3+, Ki67+,
CD45+, and Gal-3+ cells decreased in the SVZ after
cuprizone treatment which is in contrast to TMEV [16]
and most other disease models. The decrease was
Hillis et al. Journal of Neuroinflammation  (2016) 13:190 Page 12 of 15remarkable since immediately above the SVZ in the CC
Phi3+, Ki67+, CD45+, and Gal-3+, cell numbers in-
creased. Because inflammation was decreased in the
SVZ, we hypothesized that proliferation would increase
in the niche [18]; however, it decreased after cuprizone
treatment, suggesting the relationship between inflam-
mation and proliferation in the niche is complex. We
also showed that SVZ proliferation was not affected in
Gal-3 knockouts in vivo or in the neurosphere assay.
This is in line with our previous work showing that Gal-
3 loss does not directly affect SVZ proliferation [16, 22].
However, we labeled SVZ cells with multiple doses of
BrdU and found that 3 weeks after cuprizone adminis-
tration, Gal-3−/− mice had significantly fewer cells in the
SVZ compared to WT controls, suggesting Gal-3 limits
emigration of SVZ cells.
The decrease in Gal-3+ SVZ cells was probably not
due to the decrease in CD45+ cells since the large ma-
jority of SVZ Gal-3 expression is not in CD45+ micro-
glial cells but in SVZ astrocytes and ependymal cells
[22]. Interestingly, we showed that cuprizone induced
activation of GFAP expression and morphological
changes in the SVZ consistent with reactive astrocytosis.
Gal-3 expression can increase in striatal astrocytes in re-
sponse to TMEV [16]. In these experiments, despite the
SVZ astrocyte reactivity, Gal-3 expression actually de-
creased, suggesting Gal-3 is not required for SVZ astro-
cytic reactivity. Similarly, Gal-3 knockout mice exhibited
robust increases in GFAP expression both in the SVZ
and the CC. A recent study showed that stab wound
injury-induced reactive astrocytosis in the cerebral cor-
tex depends on Gal-3 expression [41]. Thus, it is likely
that Gal-3 has different effects on astrocyte reactivity de-
pending on the brain region or type of pathology.
This work adds to the growing list of studies revealing
the SVZ as a unique inflammatory niche. We were sur-
prised a number of years ago to find that SVZ microglia
are semi-activated in healthy animals [15]. We then
made the remarkable observation that traumatic brain
injury (TBI) [15] and stroke [32, 42] induce massive in-
flammation in forebrain parenchyma, but not in the ad-
jacent SVZ. This was in contrast to TMEV infection
which was associated with consistent inflammation in
the SVZ [17]. In this manuscript, we provide data sug-
gesting that SVZ microglial numbers and inflammation
are actually decreased after cuprizone treatment. We
have found that Gal-3 is expressed by the same cells in
the healthy SVZ as in disease models. It was expressed
by astrocytes and ependymal cells homeostatically, after
TBI, TMEV, stroke, and cuprizone [16, 22, 32] (and Szele
lab unpublished studies). It is particularly surprising that
few microglial cells express Gal-3 in the SVZ before or
after injury since Gal-3 has been used as a marker of ac-
tivated macrophages. Taken together, this study andprevious work shows that inflammation in the SVZ is
tightly regulated and is sensitive to pathological context.
The decrease in markers of inflammation in the SVZ
was in sharp contrast with the increased number of Gal-
3+ and CD45+ cells in the adjacent corpus callosum.
Similar sharp contrasts between indices of inflammation
in the SVZ and the adjacent CC, striatum, or cerebral
cortex have been noted in TBI and TMEV [15–17].
CD45 labels all cells in the hematopoietic lineage so is
insufficient to definitively phenotype them. Here, we
found that the number of CD45+ SVZ cells that
expressed Iba1 increased slightly after cuprizone. Since
Iba1 is associated with microglia, these data suggest that
though cuprizone decreased the number of CD45+ SVZ
cells, the relative percent of microglia increased. Our
previous work found a small number of dendritic cells
[17] and T cells [16] in the SVZ; thus, it is possible that
some of the CD45+/Iba1-negative cells we found in this
study in the SVZ belonged to one of these cell types. Al-
ternatively, a minority SVZ CD45+ microglial cells
expressed Iba1 below the level of immunohistochemical
detection. It is likely the unique extracellular molecular
environment in the SVZ selectively autoregulates inflam-
mation in the niche [16, 43, 44]. We recently demon-
strated the SVZ expresses higher levels of chemokine
ligands than adjacent regions [16]. A better understand-
ing of how inflammation is regulated in the SVZ may
help develop approaches to augment neurogenesis since
immune cells cross talk with neural cells and can be ei-
ther beneficial or detrimental to their homeostatic and
reparative functions [45].
Many types of brain injury increase SVZ proliferation
[38, 46, 47]; however, activation of neurogenesis depends
on the model, species, and level of inflammation. Inflam-
mation was originally shown to dampen adult neurogen-
esis [18, 19], but recent work has defined multiple
modes of microglial activation, some of which increase
neurogenesis [20, 21, 45]. Therefore, we were uncertain
whether the SVZ phenotype induced by cuprizone de-
scribed above would be associated with altered prolifera-
tion. The demyelination groups had significantly
diminished numbers of proliferative SVZ cells and
rebounded to control levels in the remyelination group,
suggesting a rapid return to homeostasis in the SVZ
upon cessation of cuprizone. In contrast to the SVZ, CC
proliferation increased at the 6-week and remyelination
time points. This paralleled the discrepancy between the
SVZ and CC described above and further suggests
unique regulation of inflammation in the SVZ.
The proliferative response to cuprizone in the SVZ
and the CC was not affected by loss of Gal-3. This was
supported by our in vitro data: the number and size of
SVZ neurospheres were unaffected by loss of Gal-3.
Neurospheres were prepared from P4-5 pups, and it
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growth when prepared from adults. However, loss of
Gal-3 did not alter constitutive proliferation in the adult
SVZ in three separate murine strains [16, 22]. Similar re-
sults were obtained in the MCAO model of stro-
ke—there were no differences between WT and Gal-3
nulls in SVZ or parenchymal proliferation [32]. This is
in contrast to a recent study in which loss of Gal-3
inhibited astrocyte proliferation after stab wound injury
[41]. Gal-3 binds to a large variety of proteins, has mul-
tiple functional effects depending on context, and is fre-
quently expressed de novo after brain injury, together
positioning it to have selective effects in different
contexts.
One of the key features of SVZ progenitors is their
capacity for long-distance migration to the OB and emi-
gration towards injured regions of the brain. There is
good evidence that SVZ progenitors are beneficial by a
combination of neural replacement and neuroprotection
[48, 49]. To track potential SVZ progenitor emigration,
we labeled cells with BrdU at the beginning of cuprizone
administration. The large majority of cells that are pro-
liferative and get labeled by BrdU in the forebrain before
damage are SVZ cells. Therefore, BrdU+ cells outside of
the SVZ at later time points could be inferred to have
migrated from the SVZ. Interestingly, we showed de-
creased BrdU+ cell numbers in the SVZ but increased
numbers in the CC after cuprizone. At 3 weeks, the
number of BrdU+ cells that were gone from the SVZ
was significantly greater in Gal-3−/− than in WT mice,
suggesting that Gal-3 normally inhibits emigration. This
is supported by our previous finding that lack of Gal-3
causes SVZ progenitors to switch migration from their
rostral direction to a local exploratory motility as a prel-
ude to emigration [22]. It is also consistent with our
TMEV demyelination model wherein loss of Gal-3 in-
creased SVZ progenitor emigration [16]. These data are
consistent with cuprizone inducing BrdU+ cells to mi-
grate from the SVZ to the CC.
Because of the decreased rostral migration previously
observed in Gal-3−/− mice [22], the decreased number of
BrdU+ cells in the SVZ of Gal-3−/− mice in this study
was probably not caused by greater rostral migration to-
wards the OB. We demonstrated decreased MBP im-
munofluorescence in the OB of WT mice after
cuprizone, suggesting demyelination. However, we do
not know if OB demyelination was increased in Gal-3−/−
mice relative to WTs, which could have increased rostral
migration and explained the decreased numbers of BrdU+
cells in the SVZ at 3 weeks post-cuprizone. Using immuno-
histochemistry for Gal-3 and CD45, we previously noticed
that cuprizone and TMEV caused inflammation in multiple
forebrain regions [17], such as the OB. We have other data
suggesting OB demyelination after TMEV based onreduced MBP immunofluorescence (Szele lab, unpublished
observations). The extent of OB and olfactory tract demye-
lination in MS and neuromyelitis optica patients is corre-
lated with disease severity [50]. We propose the cuprizone
and TMEV-IDD animal models will help elucidate the
pathophysiological mechanisms and functional conse-
quences of OB inflammation and demyelination in MS.
The majority of cells that emigrated from the SVZ
were likely in the oligodendrocyte lineage as many
BrdU+ labeled cells in the CC were Olig2+. There is
ample evidence that human MS and models of demye-
lination induce SVZ-derived oligodendrocytes to emi-
grate [10–13, 51]. In this study, the number of Olig2+
cells in the CC decreased at 3 weeks post-cuprizone
and then increased suggesting cuprizone initially killed
oligodendrocytes which were then replaced by SVZ-
derived oligodendrocyte precursors. Recent work has
suggested Gal-3 alters the rate of oligodendrocyte
maturation and extent of demyelination [26]. We did
not find any evidence for differences in Olig2+ cells in
the SVZ or CC between WT and Gal-3−/− mice. We
also examined the expression of the mature oligo-
dendrocyte marker CC1 [35]. We did not find that the
percent of Olig2+ cells that expressed CC1 differed
between Wt and Gal-3−/− mice. Both genotypes also
exhibited an increased percent of Olig2+ that were
CC1+ in the remyelination group. These results sug-
gest Gal-3 loss does not affect oligodendrocyte differ-
entiation. Finally, although SVZ neuroblast migration
towards demyelination has been documented [52], we
found very few BrdU+ cells in the CC that expressed
the immature neuronal marker Dcx.
A study by Hoyos and colleagues showed that loss of
Gal-3 inhibited remyelination in the CC after cuprizone
as measured by MBP, suggesting that Gal-3 normally has
a positive effect on remyelination [27]. Similar to that
study, we showed loss of MBP immunofluorescence in
the CC in the 6-week post-cuprizone group suggesting
demyelination. However, we did not find that loss of
Gal-3 affected MBP loss or return to normal values in
the CC. We are not certain what accounts for this dis-
crepancy; however, it is important to note that Hoyos
et al. performed experiments in a different Gal-3 knock-
out mouse, which lacks exon V [27], whereas the mouse
used here lacks exons II, III, and IV [53].
Conclusions
We provide further evidence in this study that inflam-
mation in the SVZ is uniquely regulated. Compared to
the recently published TMEV model of severe inflamma-
tion and demyelination [16], the effects of Gal-3 are
more subtle in the milder cuprizone demyelination.
Nevertheless, we did show here that loss of Gal-3 is as-
sociated with increased SVZ progenitor emigration to
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combined studies suggest clinical trials of molecules that
modulate Gal-3 function may be warranted.Additional files
Additional file 1: Figure S1. Gal-3 absence does not alter candidate
gene expression. A: Graph shows the relative expression of the candidate
genes Ccl2, Ccr2, Egfr, and Mmp9 in the SVZ of Gal-3+/+ and Gal-3−/−
mice. It demonstrates fold change compared to Gal-3+/+ mice for
quantities normalized to the housekeeping gene B2m. Graph shows
mean ± SEM. Graph demonstrates fold change compared to Gal-3+/+
mice. Statistics calculated as t test using SPSS. No significant differences
found. B: Gal-3 absence is not compensated by other galectins. Graph shows
qPCR comparison of SVZ galectin expression in Gal-3+/+ and Gal-3−/−
mice. It demonstrates fold change compared to Gal-3+/+ mice for
quantities normalized to the housekeeping gene B2m. Genes include
Lgals1, 3, 8, and 9, which correspond to Gal-1, 3, 8, and 9, respectively.
Statistics calculated as t test with N = 3 samples per genotype, each
sample containing pooled SVZs from four mice. Graph shows mean ±
SEM. ***p < 0.001. (TIF 9099 kb)
Additional file 2: Table S1. PHi3+ cells int he SVZ and CC after
cuprizone treatment. (JPG 380 kb)
Additional file 3: Figure S2. Ki67 and Mash1 immunohistochemistry in
the SVZ. Representative examples of Ki67 and Mash1
immunohistochemistry in the SVZ. Scale bar 50 μm. (TIF 5734 kb)
Additional file 4: Table S2. Pairwise comparisons for genotype within
region*length*genotype interaction in the SVZ. (JPG 288 kb)
Additional file 5: Table S3. Pairwise comparison for region*treatment
in the CC. (JPG 127 kb)
Additional file 6: Figure S3. Cuprizone causes loss of MBP expression
in the olfactory bulb. A and B: OB sections with MBP immunohistochemistry
from WT mice. Dotted box shows region of images in B. GL: glomerular layer,
EPL: external plexiform layer, MCL/IPL: mitral cell layer/internal plexiform layer,
GrL: granular layer. Scale bars 500 mm (A) and 100 mm (B). C: Graphs showing
percentage of pixels with fluorescence intensity above threshold in the
glomerular, external plexiform, and granular layers. Statistics calculated as
repeated-measures ANOVA with N= 6. Graphs show mean ± SEM. *p≤ 0.05,
**p≤ 0.01, ***p≤ 0.001. (TIF 18577 kb)Abbreviations
ANOVA, analysis of variance; BrdU, 5-bromo-2′-deoxyuridine; CC, corpus
callosum; CD45, complement of differentiation 45; Dcx, doublecortin; Gal-3,
galectin-3; GFAP, glial fibrillary acidic protein; Iba1, ionized calcium-binding
adapter molecule 1; LV, lateral ventricle; MBP, myelin basic protein; MS,
multiple sclerosis; OB, olfactory bulb; Olig2, oligodendrocyte lineage transcription
factor 2; PHi3, phosphohistone 3; qPCR, quantitative polymerase chain reaction;
RMS, rostral migratory stream; SEM, standard error of the mean; SVZ, subventricular
zone; TAP, transit amplifying progenitor
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